Publications by authors named "A Mima"
Article Synopsis
- Membranous proliferative glomerulonephritis (MPGN) is a rare kidney condition characterized by specific pathological changes, observed in a 77-year-old man with mild proteinuria and hematuria.
- Laboratory tests indicated elevated MPO-ANCA levels and a renal biopsy showed distinct features that confirmed MPGN type 3.
- The patient responded well to treatment with an SGLT2 inhibitor and the case raises questions about the association between high MPO-ANCA levels and latent tuberculosis infection, suggesting a potential link that needs further investigation.*
Introduction: Diabetic kidney disease (DKD) is an important complication of diabetes as it results in end-stage renal disease; hence, several drugs have been developed for its treatment. However, even with treatment with renin-angiotensin system inhibitors and sodium-glucose cotransporter-2 inhibitors, the residual risk of DKD remains. While this risk is an issue, the renoprotective effects of finerenone, a novel non-steroidal mineralocorticoid receptor antagonist, are becoming evident.
View Article and Find Full Text PDFBackground/aim: Vildagliptin is one of the dipeptidyl peptidase-4 (DPP-4) inhibitors that have been shown to improve hyperglycemia in clinical trials among patients with type 2 diabetes. However, few studies have examined the efficacy of vildagliptin in patients with diabetic kidney disease (DKD).
Patients And Methods: Eight patients with DKD received oral vildagliptin 50-100 mg/day.
Objective: Tirzepatide is an injectable peptide approved by the US Food and Drug Administration for the treatment of Type 2 diabetes (T2DM). Its weight-loss effect primarily targets fat reduction; however, such effect on patients with chronic kidney disease (CKD) undergoing haemodialysis (HD) has not been reported.
Methods: Nine patients with CKD undergoing HD received weekly tirzepatide doses (2.
Introduction Dotinurad is being developed as a selective uric acid reabsorption inhibitor. However, its effect on lowering serum uric acid (UA) levels in chronic kidney disease (CKD) patients with severe renal dysfunction is unknown. Therefore, the purpose of this study was to determine the effect of dotinurad on renal function in CKD patients with an estimated glomerular filtration rate (eGFR) below 25 mL/min/1.
View Article and Find Full Text PDF